Brokerages Set Orthofix Medical Inc. (NASDAQ:OFIX) Price Target at $21.50

Key Points

• Orthofix Medical Inc. (NASDAQ:OFIX) has a consensus rating of "Buy" among five brokerages, including three buy ratings and one strong buy rating.
• The average 1-year target price for the stock is $21.50, reflecting analysts' optimism about its potential performance.
• Recent insider activity saw Aviva Mcpherron selling 3,728 shares at an average price of $10.51, reducing her ownership stake by 7.45%.

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) has been given an average rating of "Buy" by the five research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $21.50.

Several brokerages recently commented on OFIX. Wall Street Zen raised shares of Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Barrington Research raised shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 target price on the stock in a research note on Monday, June 23rd. Finally, JMP Securities reissued a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th.

Orthofix Medical Stock Performance

NASDAQ:OFIX traded down $0.31 on Friday, hitting $14.30. The company's stock had a trading volume of 170,468 shares, compared to its average volume of 336,433. The company has a current ratio of 2.67, a quick ratio of 1.50 and a debt-to-equity ratio of 0.38. The stock has a fifty day moving average of $12.68 and a two-hundred day moving average of $13.30. The firm has a market capitalization of $564.61 million, a P/E ratio of -4.51 and a beta of 0.86. Orthofix Medical has a one year low of $10.24 and a one year high of $20.73.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.40). Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. The business had revenue of $203.12 million during the quarter, compared to the consensus estimate of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. Research analysts predict that Orthofix Medical will post -2.81 earnings per share for the current year.

Insider Activity at Orthofix Medical

In related news, insider Aviva Mcpherron sold 3,728 shares of Orthofix Medical stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the sale, the insider directly owned 46,322 shares in the company, valued at approximately $486,844.22. This trade represents a 7.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Orthofix Medical

Institutional investors have recently added to or reduced their stakes in the stock. Engine Capital Management LP raised its position in Orthofix Medical by 13.6% in the second quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company's stock worth $47,406,000 after acquiring an additional 510,281 shares during the period. Rubric Capital Management LP boosted its holdings in shares of Orthofix Medical by 0.7% in the second quarter. Rubric Capital Management LP now owns 3,721,715 shares of the medical device company's stock worth $41,497,000 after acquiring an additional 26,769 shares during the period. Paradigm Capital Management Inc. NY raised its stake in shares of Orthofix Medical by 34.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 3,340,600 shares of the medical device company's stock valued at $37,248,000 after purchasing an additional 858,900 shares during the period. Armistice Capital LLC lifted its holdings in Orthofix Medical by 0.5% during the 2nd quarter. Armistice Capital LLC now owns 2,978,000 shares of the medical device company's stock worth $33,205,000 after purchasing an additional 14,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Orthofix Medical by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 2,181,313 shares of the medical device company's stock worth $35,577,000 after purchasing an additional 54,528 shares in the last quarter. Institutional investors own 89.76% of the company's stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.